Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(2.11)
# 2,958
Out of 5,152 analysts
41
Total ratings
45.95%
Success rate
-5.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $101 → $126 | $87.84 | +43.44% | 5 | Mar 4, 2026 | |
| ABBV AbbVie | Maintains: Outperform | $232 → $228 | $232.35 | -1.87% | 6 | Feb 5, 2026 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $38 → $36 | $15.20 | +136.84% | 1 | Dec 15, 2025 | |
| VERA Vera Therapeutics | Maintains: Outperform | $75 → $97 | $38.86 | +149.61% | 1 | Dec 8, 2025 | |
| EVMN Evommune | Initiates: Outperform | $40 | $25.04 | +59.74% | 1 | Dec 1, 2025 | |
| FBRX Forte Biosciences | Initiates: Outperform | $65 | $30.55 | +112.77% | 1 | Nov 25, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $775 → $910 | $727.25 | +25.13% | 5 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $20 → $14 | $1.38 | +918.18% | 4 | Sep 22, 2025 | |
| PRQR ProQR Therapeutics | Initiates: Outperform | $5 | $1.69 | +196.74% | 1 | Apr 29, 2025 | |
| CABA Cabaletta Bio | Downgrades: In-Line | $15 → $6 | $3.20 | +87.79% | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $179 → $170 | $16.22 | +948.41% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $5.63 | +255.56% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $201 → $206 | $260.16 | -20.82% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $3.14 | +601.75% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $3.04 | +228.95% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $70.66 | -15.09% | 1 | Oct 5, 2022 |
Mirum Pharmaceuticals
Mar 4, 2026
Maintains: Outperform
Price Target: $101 → $126
Current: $87.84
Upside: +43.44%
AbbVie
Feb 5, 2026
Maintains: Outperform
Price Target: $232 → $228
Current: $232.35
Upside: -1.87%
Dyne Therapeutics
Dec 15, 2025
Maintains: Outperform
Price Target: $38 → $36
Current: $15.20
Upside: +136.84%
Vera Therapeutics
Dec 8, 2025
Maintains: Outperform
Price Target: $75 → $97
Current: $38.86
Upside: +149.61%
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $25.04
Upside: +59.74%
Forte Biosciences
Nov 25, 2025
Initiates: Outperform
Price Target: $65
Current: $30.55
Upside: +112.77%
argenx SE
Oct 31, 2025
Maintains: Outperform
Price Target: $775 → $910
Current: $727.25
Upside: +25.13%
Jasper Therapeutics
Sep 22, 2025
Maintains: Outperform
Price Target: $20 → $14
Current: $1.38
Upside: +918.18%
ProQR Therapeutics
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $1.69
Upside: +196.74%
Cabaletta Bio
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $3.20
Upside: +87.79%
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $16.22
Upside: +948.41%
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $5.63
Upside: +255.56%
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $260.16
Upside: -20.82%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $3.14
Upside: +601.75%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $3.04
Upside: +228.95%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $70.66
Upside: -15.09%